AI/ML Innovations Secures U.S. Patent for Advanced AI-Based ECG Analysis Technologies

AI/ML Innovations Inc. ("AIML"), a Toronto-based leader in artificial intelligence applications for physiological signal interpretation, has announced that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has been granted U.S. Patent No. 12,622,625 B2. The patent, titled "Machine Learning Techniques for Electrocardiogram (ECG) Analysis," was issued by the United States Patent and Trademark Office and expands NeuralCloud’s intellectual property protection around AIML’s proprietary AI-based ECG analysis architecture.

This newly granted patent covers a range of machine learning techniques applied to ECG data, including methods for receiving ECG signals from wearable devices or other sources, encoding the data into numeric representations, and processing these representations through trained machine learning models. The patent’s scope includes generating outputs such as denoised ECG signals, rhythm classifications, sample-level ECG labels, waveform characteristics, and comprehensive report outputs.

The patent builds upon AIML’s broader IP strategy to safeguard foundational technologies that enable high-quality ECG interpretation in both healthcare and research environments. As ECG data increasingly transitions from traditional clinical settings to wearable devices, remote monitoring platforms, cloud infrastructures, and decentralized care models, the ability to accurately clean, label, classify, and structure cardiac data has become critical.

AIML emphasizes the commercial significance of this patent, noting that it protects technologies at the intersection of AI, ECG signal processing, wearable monitoring, and cardiac workflow automation. These capabilities are relevant to multiple market segments, including ambulatory monitoring, Holter reporting, remote patient monitoring, telecardiology, clinical trials, digital health platforms, and original equipment manufacturer (OEM) integrations.

The patent describes systems and methods applicable across wearable devices, remote computing environments, and clinical software workflows. Specific AI-driven modules covered include ECG denoising, rhythm classification, waveform boundary determination, sample-level ECG labeling, waveform metric determination, user interface generation, and report generation.

Additionally, the patent contemplates flexible architectures where ECG data may be captured from wearable devices and processed locally, remotely, or via hybrid workflows. This flexibility aligns with NeuralCloud’s product strategy of supporting device-agnostic and scalable deployments across clinics, hospitals, telehealth networks, OEM partners, research institutions, remote patient monitoring programs, and other healthcare settings.

This patent further supports AIML’s development of its core cardiac technology platforms, including MaxYield™, CardioYield™, and Insight360™.

In a statement, AIML highlighted the significance of the patent issuance: "This issuance reflects AIML’s continued progress in building a defensible and expanding IP position around AI-driven cardiac signal interpretation. Our first issued patent established protection around foundational ECG wave-property identification. This new patent extends that protection into broader machine learning techniques for ECG analysis, including denoising, classification, labeling, wearable-device implementation, and reporting. We believe this strengthens our competitive position as we continue to advance regulatory pathways and commercial opportunities."

The company further noted, "This patent is an important addition to our intellectual property portfolio and further demonstrates the depth of innovation behind NeuralCloud’s ECG technology. By protecting methods that support ECG denoising, rhythm classification, sample-level labeling, and downstream reporting, this patent reinforces the technical foundation of our platform and our ability to deliver scalable, high-quality cardiac insights across clinical and remote monitoring environments."

Separately, AIML announced that it has entered into agreements with certain service providers to issue an aggregate of 3,560,334 common shares at a deemed price of CAD 0.05 per share. These shares are being issued in consideration of past services and to satisfy outstanding indebtedness. The issuance remains subject to approval by the Canadian Securities Exchange (CSE).

Insiders of AIML intend to purchase, directly or indirectly, an aggregate of 1,933,334 of these shares, resulting in a "related party transaction" under Multilateral Instrument 61-101 (MI 61-101). However, AIML is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to specific exemptions applicable to companies listed on the CSE where the fair market value involved does not exceed 25% of the company’s market capitalization.

AIML cautioned that this news release does not constitute an offer to sell or solicitation to buy securities in any jurisdiction where such offers would be unlawful, including the United States. The securities described have not been registered under the U.S. Securities Act of 1933 or any state securities laws and may not be offered or sold in the U.S. or to U.S. persons unless registered or exempt.

AI/ML Innovations Inc. is a technology company focused on developing AI and neural-network solutions for digital health. Its proprietary technology applies advanced signal processing and deep learning to improve the quality of complex biometric and cardiac signal data. AIML’s shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).